Brokers Issue Forecasts for GPCR Q3 Earnings

Key Points

• Lifesci Capital has forecasted Structure Therapeutics Inc. will report Q3 2025 earnings of ($0.35) per share, with the company expected to have a full-year loss of ($0.82) EPS.
• Several brokerages, including Guggenheim and Cantor Fitzgerald, have revised their price targets for Structure Therapeutics, indicating a strong consensus rating of "Buy" with an average price target of $75.71.
• Institutional investors hold a significant 91.78% stake in Structure Therapeutics, with hedge funds recently increasing their positions in the company.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) - Equities researchers at Lifesci Capital issued their Q3 2025 earnings estimates for Structure Therapeutics in a research report issued to clients and investors on Monday, September 8th. Lifesci Capital analyst P. Dolezal forecasts that the company will post earnings of ($0.35) per share for the quarter. Lifesci Capital has a "Strong-Buy" rating on the stock. The consensus estimate for Structure Therapeutics' current full-year earnings is ($0.82) per share. Lifesci Capital also issued estimates for Structure Therapeutics' Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.29) EPS.

A number of other brokerages have also recently issued reports on GPCR. Guggenheim decreased their target price on Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Cantor Fitzgerald restated an "overweight" rating and set a $65.00 price objective on shares of Structure Therapeutics in a report on Monday, June 23rd. JMP Securities cut their price objective on Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating on the stock in a report on Thursday, August 7th. Finally, HC Wainwright cut their price objective on Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $75.71.

Structure Therapeutics Trading Down 1.7%

Shares of Structure Therapeutics stock opened at $20.89 on Thursday. The company's 50-day moving average price is $18.89 and its two-hundred day moving average price is $20.68. Structure Therapeutics has a 52 week low of $13.22 and a 52 week high of $45.37. The stock has a market cap of $1.20 billion, a PE ratio of -19.90 and a beta of -1.88.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.08).

Hedge Funds Weigh In On Structure Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Vestal Point Capital LP grew its stake in shares of Structure Therapeutics by 50.0% in the 4th quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company's stock valued at $46,782,000 after buying an additional 575,000 shares in the last quarter. Pacific Heights Asset Management LLC bought a new stake in shares of Structure Therapeutics in the 2nd quarter valued at approximately $9,540,000. Orbimed Advisors LLC grew its stake in shares of Structure Therapeutics by 49.5% in the 2nd quarter. Orbimed Advisors LLC now owns 1,199,300 shares of the company's stock valued at $24,873,000 after buying an additional 397,272 shares in the last quarter. Readystate Asset Management LP grew its stake in shares of Structure Therapeutics by 129.9% in the 1st quarter. Readystate Asset Management LP now owns 481,241 shares of the company's stock valued at $8,330,000 after buying an additional 271,899 shares in the last quarter. Finally, Handelsbanken Fonder AB grew its stake in shares of Structure Therapeutics by 130.3% in the 1st quarter. Handelsbanken Fonder AB now owns 380,000 shares of the company's stock valued at $6,578,000 after buying an additional 215,000 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.